Detalhe da pesquisa
1.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica;
109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37731379
2.
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Transplant Cell Ther;
2024 Jun 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38834151
3.
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Blood Adv;
6(24): 6109-6119, 2022 12 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35939783
4.
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Blood Cancer J;
13(1): 158, 2023 10 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37833271